ORIC PHARMACEUTICALS INC's ticker is ORIC and the CUSIP is 68622P109. A total of 81 filers reported holding ORIC PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $693,633 | -21.7% | 114,650 | +0.5% | 0.00% | – |
| Q2 2023 | $885,409 | +1067.1% | 114,099 | +757.3% | 0.00% | – |
| Q1 2023 | $75,861 | -3.2% | 13,309 | 0.0% | 0.00% | – |
| Q4 2022 | $78,390 | +82.3% | 13,309 | 0.0% | 0.00% | – |
| Q3 2022 | $43,000 | -28.3% | 13,309 | 0.0% | 0.00% | – |
| Q2 2022 | $60,000 | -89.8% | 13,309 | -87.9% | 0.00% | – |
| Q1 2022 | $590,000 | -64.4% | 110,440 | -2.0% | 0.00% | – |
| Q4 2021 | $1,656,000 | -28.5% | 112,689 | +1.7% | 0.00% | – |
| Q3 2021 | $2,317,000 | +60.0% | 110,814 | +35.4% | 0.00% | – |
| Q2 2021 | $1,448,000 | -23.0% | 81,819 | +6.6% | 0.00% | – |
| Q1 2021 | $1,881,000 | -24.6% | 76,787 | +4.1% | 0.00% | -100.0% |
| Q4 2020 | $2,496,000 | +342.6% | 73,731 | +226.5% | 0.00% | – |
| Q3 2020 | $564,000 | -26.4% | 22,584 | -0.5% | 0.00% | – |
| Q2 2020 | $766,000 | – | 22,706 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 4,768,181 | $99,703,000 | 11.34% |
| Euclidean Capital LLC | 777,193 | $16,251,000 | 7.90% |
| Memorial Sloan Kettering Cancer Center | 602,272 | $12,594,000 | 7.85% |
| Invus Financial Advisors, LLC | 1,007,575 | $21,068,000 | 5.64% |
| EcoR1 Capital, LLC | 3,468,944 | $72,536,000 | 2.52% |
| EMERALD ADVISERS, LLC | 726,236 | $15,186,000 | 0.55% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 742,666 | $15,529,000 | 0.54% |
| Orbimed Advisors | 2,337,574 | $48,879,000 | 0.54% |
| Casdin Capital, LLC | 601,515 | $12,578,000 | 0.31% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 53,000 | $1,104,000 | 0.27% |